Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results: Subretinal Gene Therapy AGTC-501 for XLRP Ph 1/2 24M Results.

AGTC-501 - AGTC

http://www.ncbi.nlm.nih.gov/pubmed/39643074

Abraham Scaria; Alessandro Iannaccone; Andreas Lauer; Antonio Yaghy; Darin Curtiss; David Birch; JungAh Jung; Mark E Pennesi; Nadia K Waheed; Paul Yang; Rajiv Anand; Robert Sisk

Dec 8, 2024